TABLE 5.

Numbers of N-linked glycosylation sites and V region lengths for breast milk and plasma virus variants from chronically HIV-infected, lactating womenb

SubjectSample typeMedian no. of gp160 N-glycosylation sites (range)P valueMedian V region length (range)P value
0301Plasma32 (31-33)0.04148 (143-152)0.01
Milk31 (29-32)146.5 (139-148)
0404aPlasma31 (28-33)0.07144.5 (141-149)0.9
Milk30 (28-33)145 (141-146)
0601Plasma33 (30-36)0.005148 (138-157)0.008
Milk30 (30-36)142 (142-156)
0702Plasma25 (24-27)0.68128 (127-131)0.08
Milk25 (25-27)128 (127-132)
1209aPlasma29 (24-35)0.32149 (138-161)0.08
Milk25 (24-32)143 (138-160)
3009Plasma27 (26-34)0.03144 (142-160)0.002
Milk32 (26-34)160 (142-160)
3305Plasma33 (29-34)0.10165 (146-173)0.006
Milk31 (29-33)161 (134-167)
3404Plasma30.5 (29-33)0.07218 (218-235)0.09
Milk30 (27-31)218 (214-236)
3902Plasma32.5 (27-33)0.006161 (137-167)0.03
Milk33 (31-34)163 (151-167)
4403aPlasma28 (27-33)0.06141 (139-149)0.12
Milk28 (25-32)141 (122-153)
4707Plasma32 (25-38)0.84150 (130-161)0.62
Milk27 (25-35)130 (130-158)
5807Plasma31 (27-34)0.21151 (128-156)0.12
Milk29 (27-34)132 (128-155)
All subjectsPlasma31 (24-38)0.14148 (127-235)0.19
Milk30 (24-36)143 (122-236)
  • a Breast milk-transmitting subject.

  • b Subjects with laboratory evidence of subclinical mastitis are indicated with shading. Significant P values (<0.05) are shown in bold.